Information Provided By: 
Fly News Breaks for December 1, 2019
AGN, RVNC
Dec 1, 2019 | 21:10 EDT
Goldman Sachs analyst Terence Flynn initiated coverage of Revance Therapeutics (RVNC) with a Buy rating and $25 price target. The company is is developing DaxibotulinumtoxinA, an injectable botulinum toxin that would compete with Allergan's (AGN) Botox and other smaller players in the $4B-plus global neuromodulator market, Flynn tells investors in a research note. Revance is requesting a six month duration versus three-to-four months for currently marketed neurotoxins, which will be a key point of differentiation, adds the analyst.
News For RVNC;AGN From the Last 2 Days
There are no results for your query RVNC;AGN
